ViewRay price target lowered to $2 from $5.50 at Morgan Stanley

Morgan Stanley analyst Cecilia Furlong lowered the firm’s price target on ViewRay to $2 from $5.50 and keeps an Equal Weight rating on the shares after management lowered its 2023 revenue growth and EBITDA loss outlook while concurrently announcing the company will look to evaluate strategic alternatives. The firm views cash concerns as "a material overhang on shares until further clarity emerges," the analyst tells investors.